PDS Biotechnology Corp. (PDSB)

Over the past six months, PDS Biotechnology Corp.'s stock price has been impacted by several events. In May 2026, the company announced a conference call for its Q1 2026 financial results. In April 2026, positive interim Phase 2 clinical trial data for PDS01ADC led to a significant stock increase. In March 2026, the company reported its full-year 2025 financial results and amended its Phase 3 trial protocol. In February 2026, the company announced a conference call for its Q4 and full-year 2025 financial results. In January 2026, positive interim Phase 2 clinical trial data for PDS0101 was announced.

Traditional demand seasonality is not applicable to PDS Biotechnology Corp.'s current business model as its products are in clinical trials and not yet commercialized. The company's revenue generation is not tied to seasonal product sales or service demand.

PDS Biotechnology Corp. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for various cancers, utilizing its Versamune® platform technology. Its major product candidates include PDS0101, PDS01ADC, PDS0102, PDS0103, and PDS0202.

PDS Biotechnology Corp. is headquartered in Princeton, New Jersey, United States, and its operations are principally involved in drug discovery within the United States.

PDS Biotechnology's brand reputation has been influenced by positive clinical advancements and a regulatory notice. Positive interim Phase 2 clinical trial data for PDS01ADC and PDS0101 has positively impacted its reputation. The receipt of a Nasdaq notice for minimum bid price deficiency in March 2026 could have a negative impact on its reputation.

PDS Biotechnology Corp.'s ownership is a mix of institutional, retail, and individual investors. Major institutional shareholders include Armistice Capital, Llc, Vanguard Group Inc, and BlackRock, Inc. Key individual insider owners include James Healy, Anders D. Hove and Liam Ratcliffe. Retail investors hold a significant portion of the stock.